UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-37761 Vistagen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 (I.R.S. E ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies LLC Timothy Lugo - William Blair & Company LLC Operator Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VISTAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Operator Good day, and welcome to the VistaGen Second Quarter Fiscal Year 2023 Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-37761 VISTAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2023 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Mark Flather – Vice President-Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer Conference Call Participants Brian Skorney – Baird Operator Welcome to the VistaGen Therapeutics First Quarter Fiscal Year 2023 Results Conference Call. [Operator Instructions] I’ll now turn the call over to your host, Mark Flather, Vice President of Investor Rel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2022 Earnings Conference Call June 23, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies LLC Lachlan Hanbury-Brown - William Blair & Company, LLC Luke Herrmann - Robert W. Baird & Co. Michael Okunewitch - Maxim Group LLC Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Nevada 20-5093315 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the fiscal year ended: March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commis ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2022 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Lachlan Hanbury-Brown - William Blair Luke Herrmann - Baird Joanne Lee - Maxim Group Operator Greetings and welcome to VistaGen Therapeutics’ Third Quarter of Fiscal Year 2 ...